PriceTargets.com logo

Immunome - IMNM Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $33.45
  • Forecasted Upside: 65.19%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$20.25 As of 03/19/2026 11:50 AM ET
▼ -0.368 (-1.78%)

This chart shows the closing price for IMNM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Immunome Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMNM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMNM

Analyst Price Target is $33.45
▲ +65.19% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Immunome in the last 3 months. The average price target is $33.45, with a high forecast of $40.00 and a low forecast of $22.00. The average price target represents a 65.19% upside from the last price of $20.25.

This chart shows the closing price for IMNM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 polled investment analysts is to moderate buy stock in Immunome. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/17/2026
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/4/2026Craig HallumBoost TargetBuy ➝ Buy$33.00 ➝ $36.00
3/4/2026StephensLower TargetOverweight ➝ Overweight$33.00 ➝ $30.00
2/12/2026HC WainwrightInitiated CoverageBuy$40.00
2/12/2026HC WainwrightInitiated CoverageBuy$40.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/15/2026WedbushReiterated RatingOutperform ➝ Outperform$31.00
12/16/2025Lake Street CapitalBoost TargetBuy ➝ Buy$22.00 ➝ $32.00
12/16/2025GuggenheimBoost TargetBuy ➝ Buy$25.00 ➝ $35.00
12/16/2025EvercoreBoost TargetOutperform ➝ Outperform$18.00 ➝ $40.00
12/15/2025Leerink PartnersSet Target$40.00
12/1/2025Truist FinancialInitiated CoverageBuy$36.00
11/17/2025StephensBoost TargetOverweight ➝ Overweight$25.00 ➝ $33.00
11/7/2025WedbushReiterated RatingOutperform$21.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/22/2025The Goldman Sachs GroupInitiated CoverageBuy$26.00
9/22/2025The Goldman Sachs GroupInitiated CoverageBuy$26.00
9/18/2025WedbushReiterated RatingOutperform$21.00
9/5/2025Craig HallumInitiated CoverageBuy$26.00
8/25/2025GuggenheimReiterated RatingBuy ➝ Buy$25.00
8/22/2025EvercoreInitiated CoverageOutperform$18.00
8/7/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$23.00 ➝ $22.00
8/7/2025WedbushReiterated RatingOutperform$21.00
5/13/2025WedbushReiterated RatingOutperform$33.00 ➝ $21.00
4/2/2025Lake Street CapitalInitiated CoverageBuy$23.00
3/20/2025WedbushReiterated RatingOutperform ➝ Outperform$33.00 ➝ $33.00
3/20/2025StephensReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.00
3/20/2025GuggenheimLower TargetBuy ➝ Buy$35.00 ➝ $25.00
3/11/2025Lifesci CapitalInitiated CoverageOutperform$20.00
3/10/2025WedbushReiterated RatingOutperform$33.00
1/13/2025WedbushReiterated RatingOutperform$33.00
11/14/2024Piper SandlerLower TargetOverweight ➝ Overweight$23.00 ➝ $21.00
11/8/2024StephensInitiated CoverageOverweight$30.00
10/25/2024WedbushReiterated RatingOutperform ➝ Outperform$33.00 ➝ $33.00
8/13/2024WedbushReiterated RatingOutperform ➝ Outperform$33.00 ➝ $33.00
8/13/2024Piper SandlerLower TargetOverweight ➝ Overweight$27.00 ➝ $23.00
7/25/2024WedbushReiterated RatingOutperform$33.00
5/31/2024Piper SandlerInitiated CoverageOverweight$27.00
5/14/2024WedbushReiterated RatingOutperform$33.00
4/30/2024JPMorgan Chase & Co.Initiated CoverageOverweight$24.00
4/15/2024GuggenheimInitiated CoverageBuy$35.00
4/1/2024WedbushBoost TargetOutperform ➝ Outperform$27.00 ➝ $33.00
1/29/2024Leerink PartnersReiterated RatingOutperform
1/29/2024Leerink PartnersInitiated CoverageOutperform$30.00
1/23/2024WedbushBoost TargetOutperform ➝ Outperform$12.00 ➝ $19.00
1/8/2024WedbushReiterated RatingOutperform$12.00
12/19/2023WedbushInitiated CoverageOutperform$12.00
7/10/2023Chardan CapitalReiterated RatingBuy
5/15/2023Cantor FitzgeraldReiterated RatingOverweight
3/16/2023Chardan CapitalLower TargetBuy$9.00 ➝ $8.00
5/13/2022Chardan CapitalLower Target$16.00 ➝ $9.00
5/9/2022Cantor FitzgeraldReiterated RatingOverweight
3/30/2022Chardan CapitalLower Target$21.00 ➝ $16.00
1/11/2022Cantor FitzgeraldLower Target$35.00 ➝ $33.00
10/29/2021Cantor FitzgeraldInitiated CoverageOverweight$35.00
8/20/2021Chardan CapitalBoost TargetBuy$18.00 ➝ $21.00
7/7/2021Chardan CapitalReiterated RatingBuy
(Data available from 3/19/2021 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
8/21/2025
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2025
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/19/2025
  • 3 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 11 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026

Current Sentiment

  • 11 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Immunome logo
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Read More

Today's Range

Now: $20.25
Low: $20.05
High: $20.63

50 Day Range

MA: $22.77
Low: $20.14
High: $26.97

52 Week Range

Now: $20.25
Low: $5.15
High: $27.65

Volume

92,149 shs

Average Volume

1,480,149 shs

Market Capitalization

$2.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Immunome?

The following Wall Street analysts have issued reports on Immunome in the last twelve months: Craig Hallum, Evercore Inc, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Lake Street Capital, Leerink Partners, Stephens, The Goldman Sachs Group, Inc., Truist Financial Corporation, Wall Street Zen, Wedbush, and Weiss Ratings.
View the latest analyst ratings for IMNM.

What is the current price target for Immunome?

0 Wall Street analysts have set twelve-month price targets for Immunome in the last year. Their average twelve-month price target is $33.45, suggesting a possible upside of 65.2%. Evercore Inc has the highest price target set, predicting IMNM will reach $40.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $22.00 for Immunome in the next year.
View the latest price targets for IMNM.

What is the current consensus analyst rating for Immunome?

Immunome currently has 1 sell rating and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IMNM.

What other companies compete with Immunome?

Other companies that are similar to Immunome include Abivax, ImmunityBio, Qiagen, Praxis Precision Medicines and Axsome Therapeutics. Learn More about companies similar to Immunome.

How do I contact Immunome's investor relations team?

The company's listed phone number is 610-321-3700 and its investor relations email address is [email protected]. The official website for Immunome is immunome.com. Learn More about contacing Immunome investor relations.